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Enteric infections caused by Salmonella and Shigella are 
endemic in Turkey. Salmonella gastroenteritis is usually 
self-limiting and does not require antimicrobial therapy, 
except for some severely ill patients or patients who 
have underlying diseases [ 11. Ampicillin, chlor- 
amphenicol and trimethoprim-sulfamethoxazole are 
the antibiotics of choice for typhoid fever and some 
bacterial enteritis for which therapy is indicated [2,3]. 
High resistance rates in non-typhi Salmonella and 
Shigella strains against ampicain, chloramphenicol and 
trimethoprim-sulfamethoxazole have been reported 
[4--81. These long-used antimicrobials are being 
replaced by quinolones, as they have excellent activity 
against enteric pathogens, high intestinal luminal 
concentrations and good intracellular penetration. 
However, there are alarming reports of reduced 
susceptibility and even resistance of Salmonella strains to 
quinolones [9, lo]. We determined the antimicrobial 
resistance of Salmonella and Shigella strains isolated from 
seven different centers in Turkey. 
One hundred and ninety-two Salmonella and 
Shigella strains isolated between August 1994 and 
September 1995 were used in the study. Nineteen 
Salmonella typhi and 82 non-typhi Salmonella strains (49 
serogroup B, 26 serogroup D, four serogroup A, two 
serogroup C and one serogroup E) were isolated from 
blood and stool specimens. Shigella strains (53 Shigella 
sonnei, 33 Shigella jlexneri, four Shigella boydii and one 
Shigella dysenteriae) were all stool isolates. There were 
no duplicate isolates f k m  the same patient. The age of 
the patients ranged from 12 to 76 years. All of the 
Salmonella and Shigella strains were isolated from 
community-acquired infections. The bacteria from all 
centers were transported in Mueller-Hinton agar to the 
study center. The strains were checked for purity and 
biochemical characteristics and serotyped by using 
standard type-specific antisera (Difco, Detroit, MI, 
USA) [ll]. 
In vitro susceptibilities of Salmonella and Shigella 
strains against ampicillin, chloramphenicol, ofloxacin, 
ciprofloxacin and pefloxacin were determined by a 
broth microdilution method, whereas agar dilution was 
used for trimethoprim-sulfamethoxazole according 
to the instructions of the NCCLS [12]. Escherichia 
coli ATCC 25922 was used as the control strain. Mini- 
mum inhibitory concentrations (MICW) of ampicdin, 
chloramphenicol, ofloxacin, ciprofloxacin, pefloxacin 
and trimethoprim-sulfamethoxazole for Salmonella and 
Shigella strains and the resistance rates are given in 
Table 1. 
Three of 19 (16%) Salmonella typhi isolates were 
resistant to ampicillin, chloramphenicol and tri- 
methoprim-sulfamethoxazole. Ampicillin and chlor- 
amphenicol resistance among group B Salmonella strains 
was more striking than that of trimethoprim-sulfa- 
methoxazole. All Salmonella isolates were susceptible to 
the quinolones tested. 
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Table 1 In vitro activity of various antibotics against Salmonella and Shigella strains 
Bacteria Antibiotic MIC9o (mg/L) Resistance (%) 
Salmonella typhi 
(n= 19) 
Salmonella 
serogroup B 
(n=49) 
Salmonella 
serogroup D 
(n=26) 
Salmonella 
serogroup ACE 
(n=7) 
Shigella Jexneri 
(n=33) 
Shigella sonnei 
(n=53) 
Ampicillin 
Chloramphenicol 
Trimethoprimsulfamethoxazole 
Ofloxacin 
Ciprofloxacin 
Pefloxacin 
Ampicillin 
Chloramphenicol 
Trimethoprimsulfamethoxazole 
Ofloxacin 
Ciprofloxacin 
Pefloxacin 
Ampicillin 
Chloramphenicol 
Trimethoprimsulfamethoxazole 
Ofloxacin 
Ciprofloxacin 
Pefloxacin 
Ampicillin 
Chloramphenicol 
Trimethoprimsulfamethoxazole 
Ofloxacin 
Ciprofloxacin 
Pefloxacin 
Ampicillin 
Chloramphenicol 
Trimethoprimsulfamethoxazole 
Ofloxacin 
Ciprofloxacin 
Pefloxacin 
Ampicdin 
Chloramphenicol 
Trimethoprimsulfamethoxazole 
Ofloxacin 
Ciprofloxacin 
Pefloxacin 
Shigella boydii Ampicillin 
and Shigella dysenteriae Chloramphenicol 
(n=5) Trimethoprimsulfamethoxazole 
Ofloxacin 
Ciprofloxacin 
Pefloxacin 
264  
264  
28/152 
1 
0.5 
4 
2 64 
2 64 
28/152 
0.5 
0.25 
1 
264  
32 
0.2514.75 
0.12 
0.015 
0.25 
2 64 
2 64 
28/152 
0.25 
0.12 
0.25 
2 64 
2 64 
28/152 
0.06 
0.03 
0.06 
4 
32 
28/152 
0.06 
0.008 
0.06 
t 64 
264 
28/152 
0.06 
0.03 
0.06 
16 
16 
16 
- 
- 
- 
53 
53 
16 
- 
- 
- 
23 
15 
4 
- 
- 
- 
29 
29 
29 
- 
- 
- 
85 
82 
52 
- 
- 
- 
8 
11 
64 
- 
- 
- 
20 
20 
20 
- 
- 
- 
Both shigellosis and typhoid fever are endemic 
diseases in Turkey. In 1960, 80% of the Shigella isolates 
were Shigella jlexneri. In 1989, however, 31% of the 
Shigella isolates were Shigella jlexneri and 34% were 
Shigella sonnei [13]. Our results showed that the 
resistance rate of Shigellajlexneri was very high against 
ampicillin, chloramphenicol and trimethoprim- 
sulfamethoxazole. The resistance of Shigella sonnei to 
trimethoprim-sulfamethoxazole was also remarkable. 
In a previous study published in 1994, all 16 isolates of 
Salmonella typhi were susceptible to ampicillin, chlor- 
amphenicol and trimethoprim-sulfamethoxazole, while 
in this study three out of 19 Salmonella typhi isolates were 
multiresistant. AU Salmonella isolates were found to be 
susceptible to fluoroquinolones, but with higher MIC 
levels when compared with our previous study [14]. 
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Our results suggest that ampicillin, chloramphenicol 
and trimethoprim-sulfamethoxazole should no longer 
be the antibiotics of choice for shigella infections. The 
resistance rates of Salmonella serogroups favor the use 
of quinolones in enteric fever. However, although the 
MIC90 values of quinolones for Shigella strains are stdl 
between 0.008 and 0.06 mg/L, the same values for 
Salmonella typhi and Salmonella serogroup B are higher 
(0.25--1mg/L), suggesting that there might be quino- 
lone-resistant Salmonella isolates in the near future. 
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Clinical impact of changing to an automated blood-culture 
system at a small community hospital 
Clin Microbiol Infect 1999; 5: 590-593 
Automated, near-continuous-monitoring blood-culture 
systems provide several advantages to clinical micro- 
biology laboratories, including shorter detection times, 
reduced rates of contaminant blood cultures, and a 
reduction in hands-on processing time, compared to 
manual blood-culture systems [ 1-41. However, the 
purchase of an automated system represents a significant 
expenditure for smaller hospitals. Additionally, the 
clinical impact and long-term cost-effectiveness of 
these systems have not been extensively studied. 
We investigated the clinical impact of a change 
from the Isolator system (Warnpole Laboratories, 
Cranbury, NJ, USA) to the Bactec 9240 automated 
blood-culture system (Becton Dickinson Diagnostic 
Instrument Systems, Sparks, MD, USA) at a 200-bed 
community hospital. In addition to comparing detec- 
tion times for bloodstream isolates, we reviewed charts 
to determine how early clinician notification of positive 
blood-culture results affected antibiotic utilization. We 
also compared rates of contaminant isolation during the 
use of each system, since blood-culture contaminants 
are recognized to increase costs [5] and are likely to 
contribute to the unnecessary use of glycopeptide 
antibiotics, perhaps contributing to the problem of 
glycopeptide resistance [6,7]. 
The Central Maine Medical Center is a 200-bed 
community hospital with a 16-bed intensive care unit 
and an active hematology-oncology service. The on- 
